ARTICLES
Review Article
DRUG INTERACTIONS BETWEEN COVID-19 AND PSYCHIATRIC MEDICATIONS: A MINI REVIEW
Turkish Title : DRUG INTERACTIONS BETWEEN COVID-19 AND PSYCHIATRIC MEDICATIONS: A MINI REVIEW
İz Filiz,Kulacaoglu Filiz
JNBS, 2020, 7(3), p:101-105
Coronavirus disease 2019 (COVID-19) has become a pandemic with 8.708.000 confirmed cases and, 461.715 death in the world until 21 June 2020. The SARS-CoV-2 virus which is an enveloped and single-stranded RNA virus belonging to Coronaviridea family causes multiple organ systems diseases such as respiratory, gastrointestinal, hepatic and neurological tracts in humans and, animals. With the rapid and global spread of COVID-19, the scientific authorities have developed treatment algorithms for COVID-19. Besides the supportive care, chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir, tocilizumab, azithromycin, vitamin C, Convalescent plasma therapy are frequently used off-label to treat COVID-19. For severe COVID-19 cases, US Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) Remdesivir, which is the first drug to earn the title. COVID-19 treatment may cause many side effects and drug interactions. Psychiatric diseases are also chronic diseases and psychiatric drugs may have severe interactions with COVID-19 medications. Drug interactions with psychiatric medication and neuropsychiatric side effects should be considered within the action mechanism of COVID-19 treatments. Thus, In this review, we aimed to elucidate the interactions of COVID-19 medications with the antidepressants, antipsychotics and, the other psychotropic drugs that have been frequently used in psychiatric diseases. Chloroquine, hydroxychloroquine, azithromycin, ribavirin, lopinavir/ritonavir have interactions with psychiatric medications such as antidepressants, antipsychotics, anticonvulsants and, anxiolytics in terms of QTc interval prolongation, hepatotoxicity, myelosuppression, increased or decreased concentration of medications. Remdesivir has lower interactions with most of the psychiatric drugs except St John’s Wort and some anticonvulsants. However, favipiravir is considered as the COVID-19 medication which has lower interaction and side effects in combination with psychiatric medication. The use of tocilizumab is also safe with most of the psychiatric drugs and has a positive effect on depressive symptoms, although there is a risk of hepatotoxicity.
Coronavirus disease 2019 (COVID-19) has become a pandemic with 8.708.000 confirmed cases and, 461.715 death in the world until 21 June 2020. The SARS-CoV-2 virus which is an enveloped and single-stranded RNA virus belonging to Coronaviridea family causes multiple organ systems diseases such as respiratory, gastrointestinal, hepatic and neurological tracts in humans and, animals. With the rapid and global spread of COVID-19, the scientific authorities have developed treatment algorithms for COVID-19. Besides the supportive care, chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir, tocilizumab, azithromycin, vitamin C, Convalescent plasma therapy are frequently used off-label to treat COVID-19. For severe COVID-19 cases, US Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) Remdesivir, which is the first drug to earn the title. COVID-19 treatment may cause many side effects and drug interactions. Psychiatric diseases are also chronic diseases and psychiatric drugs may have severe interactions with COVID-19 medications. Drug interactions with psychiatric medication and neuropsychiatric side effects should be considered within the action mechanism of COVID-19 treatments. Thus, In this review, we aimed to elucidate the interactions of COVID-19 medications with the antidepressants, antipsychotics and, the other psychotropic drugs that have been frequently used in psychiatric diseases. Chloroquine, hydroxychloroquine, azithromycin, ribavirin, lopinavir/ritonavir have interactions with psychiatric medications such as antidepressants, antipsychotics, anticonvulsants and, anxiolytics in terms of QTc interval prolongation, hepatotoxicity, myelosuppression, increased or decreased concentration of medications. Remdesivir has lower interactions with most of the psychiatric drugs except St John’s Wort and some anticonvulsants. However, favipiravir is considered as the COVID-19 medication which has lower interaction and side effects in combination with psychiatric medication. The use of tocilizumab is also safe with most of the psychiatric drugs and has a positive effect on depressive symptoms, although there is a risk of hepatotoxicity.
Review Article
Investigating the neuroplastic effects of treatment methods applied in cerebral palsy
Turkish Title : Serebral palsi’de uygulanan tedavi yöntemlerinin nöroplastisite etkilerinin incelendiği çalışmalar
Karakuş Arzu Burcu,Metin Barış
JNBS, 2020, 7(2), p:90-97
Cerebral Palsy (SP), formed as a result of lesions in the developing brain, has been one of the main areas of interest in pediatric physiotherapy. There are many researches and reviews about the physical and social consequences of the therapy methods used in daily life. In this review, electronic databases were scanned in PUBMED and Web of Science to examine the publications investigating the neuroplastic effects that are the equivalent of the rehabilitation applied in the brain. In a limited number of publications about research on this subject, all of the results are evidence to prove that neuroplasticity developed as a result of rehabilitation. In this review, the methods used to measure neuroplasticity are briefly mentioned and it is aimed to shed more light on one of the subjects in need of investigation.
Gelişmekte olan beyindeki lezyonlar sonucu oluşan Serebral Palsi (SP), pediatrik fizyoterapinin ana ilgi alanlarından biri olmuştur. Uygulanan terapi yöntemlerinin günlük hayattaki bedensel ve sosyal sonuçlarını içeren pek çok araştırma ve derleme mevcuttur. Bu derlemede, uygulanan rehabilitasyonun beyinlerdeki karşılığı olan nöroplastik etkileri araştıran yayınları incelemek için elektronik veri tabanları PUBMED ve Web of Science içerisinde tarama yapılmıştır. Bu konudaki araştırmalarla ilgili ulaşılan sınırlı sayıdaki yayında, sonuçların hepsi rehabilitasyon sonucu nöroplastisitenin geliştiğini delillendirir niteliktedir. Bu derlemede, nöroplastisiteyi ölçmek için kullanılan yöntemlere de kısaca değinilmiş ve araştırılmaya muhtaç konulardan birine daha ışık tutmak hedeflenmiştir.
Review Article
Turkish Title : Egzersiz ve oksitosin
Aslan Kadir Sinan,Koç Halil İbrahim,Ulucan Korkut
JNBS, 2020, 7(1), p:42-45
Oxytocin, the first sequence of the peptide hormone was extracted and synthesized in addition to the importance of oxytocin as a hormone. It was synthesized for the first time in 1953 by Vinced du Vigneud, and in 1955 received the Nobel Prize. The effect of oxytocin on psychological disorders and behavior has been observed in many studies in humans and animals. In this review, the emotional commitment and behavioral role of oxytocin was examined and the effect of sport and exercise on these behaviors was investigated
Oksitosinin hormon olarak öneminin yanı sıra ilk sekansı çıkarılan ve sentezi yapılan peptid hormon olması dolayısıyla da 1950’lerden beridir üzerine çokça çalışılmış bir hormondur. 1953’de Vinced du Vigneud tarafından ilk defa sentez edilip 1955’de Nobel Ödülü almasını sağlamıştır. Oksitosinin psikolojik bozukluklar ve davranış üzerine etkisi insanlarda ve hayvanlarda yapılan birçok çalışma ile gözlemlenmiş olup, bu bozukluklardaki rolü üzerine halen araştırmalar yürütülmektedir. Bu derlemede oksitosinin duygu ve davranıştaki bağlanma rolü ele alınarak spor ve egzersizin bu davranışlara etkisi olup olmadığı incelenmiştir.
| ISSN (Print) | 2149-1909 |
| ISSN (Online) | 2148-4325 |
2020 Ağustos ayından itibaren yalnızca İngilizce yayın kabul edilmektedir.